Skip to main content
. 2012 Apr 6;3(3):336–344. doi: 10.18632/oncotarget.475

Figure 5. Kaplan-Meier survival estimates of the overall probability of survival from the time of the stage IV diagnosis.

Figure 5

(A) The median survival was 1.9 years in those patients that developed CNS metastasis compared to 3.4 years in those patients that did not. (B) In melanoma patients that developed CNS metastasis stratified by the amount of p-STAT3 expression, <1% versus ≥1%, in their systemic metastasis, no significant difference was found in survival (p = 0.37; n = 40, 108, respectively). (C) In melanoma patients that did not develop CNS metastasis, significant difference were found in survival based on the amount of p-STAT3 expression, <1% versus ≥1%, in their systemic metastasis (p = 0.049; n = 23, 128, respectively).